More importantly, OCTA provides depth-resolved information that has never before been available. OCTA has been shown to demonstrate many important clinical findings including areas of macular telangiectasia, impaired perfusion, microaneurysms, capillary remodeling, some types of intraretinal fluid, and neovascularization among many others. This unprecedented resolution coupled with the simple, fast and non-invasive imaging platform have allowed a host of basic and clinical research applications. In many cases, these images are approaching histology level resolution.

This motion-contrast imaging provides reliable, high resolution, and non-invasive images of the retinal vasculature in an efficient manner. red blood cells are moving, but neurosensory tissue is static), OCTA images are essentially motion-contrast images. Since the intensity and phase of backscattered light from retinal tissue varies based on the intrinsic movement of the tissue (e.g. OCTA images are based on the variable backscattering of light from the vascular and neurosensory tissue in the retina. OCT-Angiography (OCTA) is one such method that has rapidly gained clinical acceptance since it was approved by the FDA in late 2016. Advances in OCT technology have allowed for the creation of novel OCT-based methods. OCT has revolutionized the practice of ophthalmology over the past 10 to 20 years.

Optical angiography